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Figure 1. Cumulative proportion surviving, MLL rearrangement 
patients and patients with adverse cytogenetics.
Figure 2. Cumulative proportion surviving, t(9:11) and adverse 
cytogenetics.
Figure 3. Cumulative proportion surviving, Cr1 patients with 
t(9:11) in and patients with adverse cytogenetics.
Table 1. patients characterstics.
No (%)
age, median 
(range) 25 (14-57)
Transplanted in 
Cr1 62 (56%)
Male 64 (58%)
t (9;11) 6 (5%)
t(v;11) 4 (4%)
Favorable 
cytogenetic 32 (29%)
intermediate 
cytogenetic 55 (50%)
advers 
cytogenetic 17 (15%)
acute gVHd 37 (34%)
Chronic gVHd 49 (45%)
The t(9;11) confers good 
prognosis in AML patients 
treated with stem cell 
transplantation as com-
pared to non-t(9;11) and 
other adverse-risk abnor-
malities
To the Editor: In contrast to most 
translocations affecting the MLL 
gene, the t(9;11) is not associated 
with a markedly poor prognosis. 
Several studies revealed a very fa-
vorable outcome in the pediatric 
patient group. In adult AML, the 
t(9;11) has also been associated 
with superior survival, at least com-
pared to other 11q23 abnormali-
ties. Therefore, 11q23 rearrange-
ments in adult AML are now often 
dichotomized into t(9;11) and 
non-t(9;11), with the former being 
included in the intermediate-risk 
group and the latter in the adverse-
risk group. The proposed European 
Leukemia Net (ELN) cytogenetic 
reporting criteria reflect this divi-
sion. We investigated whether the 
outcome of AML patients treated 
with allogeneic hematopoietic stem 
cell transplantation (HSCT) with 
t(9;11) remains significantly differ-
ent from the rest of the adverse-risk 
cytogenetic group. 
Conventional cytogenetics and 
FISH data from diagnostic bone 
marrow of 110 adult AML patients 
treated with HSCT (Table 1) was 
reviewed and patients were classi-
fied according to the recommenda-
tions of the European Leukemia 
Net and included 32 with favorable 
risk, 60 in the intermediate-risk 
group, and 18 in the adverse-risk 
group. FISH confirmed MLL rear-
rangement in cases with apparent 
11q23 abnormalities. We compared 
outcome of patients with t(9;11) to 
the group of patients with adverse-
risk cytogenetics that included all 
MLL-positive non-t(9;11), among 
other cytogenetic abnormalities 
classified adverse-risk. Our study 
included 62 (56%) patients treated 
in first remission (CR1), while most 
non-CR1 AML patients were treat-
ed with HSCT in CR2. Patients 
were between 14 and 57 years, with 
median age of 25 years.
Of the 110 AML patients, 9 
(8%) had MLL gene rearrangement. 
Of these patients, only 5 (4.5% of 
all patients) had t(9;11). When all 
patients with MLL rearrangement 
were considered, patients with 
MLL abnormality had significantly 
longer overall survival (OS) (Figure 
1) when compared with adverse-
risk cytogenetics group. However, 
when patients with t(9;11) were 
excluded, there was no significant 
difference in survival (data not 
shown). In addition, when only 
patients with the t(9;11) were con-
sidered, the t(9;11) patients had 
significantly longer OS (P=.02) and 
EFS (P=.03), as compared with 
patients with adverse cytogenetics 
including all non-t(9;11) MLL-
rearranged cases (Figure 2 ). MLL 
rearrangements in the non-t(9;11) 
group included t(4;11)(q21;q23), 
t(6;11)(q27;q23) and a variant 
t(6;11;7)(q27;q23;q11.2), as well 
as t(11;17)(q23;q25). The survival 
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Oral chemotherapy in can-
cers: what about adher-
ence?
To the Editor: Oral chemothera-
py is a convenient treatment option, 
allowing spacing hospitalizations 
and avoiding complications of cen-
tral venous access; however, oral 
administration raises the problem 
of adherence, which may compro-
mise effectiveness by not following 
the proper administration schedule 
from underdosing or increasing the 
risk of toxicity from overdosing. 
We conducted this retrospective 
case-control study at the National 
Institute of Oncology in Rabat, 
from 2008 to 2010, to evaluate 
factors influencing adherence to 
oral chemotherapy. All patients 
treated with capecitabine for breast 
or digestive cancer for at least six 
months were included (Table 1). 
Nonadherence was defined as tak-
ing less than 90% or more than 
110% of the daily dose, missing 
more than two doses per cycle or not 
following the administration sched-
ule with an interval between daily 
doses of less than 8 or more than 12 
hours. SPSS version 17 was used 
for statistical tests with a P value 
<.05 considered significant. Good 
adherence was observed in 56.3% 
of patients (Table 2). Patients with 
poor adherence were significantly 
older, had a lower educational level, 
and were taking more other chronic 
medications compared with the rest 
of our sample. Sex, cancer type and 
stage had no significant influence on 
adherence (Table 3).
Nonadherence to oral chemo-
therapy may lead to toxicity, thera-
peutic resistance and tumor pro-
gression. The few studies that have 
addressed the issue indicate the 
magnitude of the problem. Poor 
adherence to tamoxifen was associ-
ated with an increased risk of death 
in breast cancer in one study.1 In 
another, adherence to oral cyclo-
phosphamide was only 57% in a 
breast cancer study.2 In 108 patients 
with hematologic malignancies, the 
adherence rate was 27% for predni-
sone and only 17% for allopurinol.3 
In a large study involving 2378 pa-
tients receiving adjuvant tamoxifen 
for breast cancer, adherence was 
87% during the first year, but only 
50% after 4 years.4 
Good adherence depends on 
several factors, including the com-
plexity of the medication regimen, 
side effects, and limited access to 
drugs.5 Patients may have a limited 
understanding of the goals of ther-
apy. Patient education is extremely 
important to therapeutic results 
and possible side effects. Poor com-
munication with the medical team 
is often correlated with poor adher-
ence.6 In a study involving 384 pa-
tients treated for chronic diseases, 
including cancers, an understand-
ing of the need for treatment was 
a more powerful factor for greater 
adherence than clinical signs or so-
cioeconomic level. Apprehension 
over side effects, as in our study, was 
correlated with lower adherence 
rates.7 Patients with poor compli-
ance to capecitabine were older than 
the rest of our sample. In a general 
population, factors associated with 
nonadherence to oral chemotherapy 
were low socioeconomic level, insti-
tutionalization, and the daily dos-
age of treatment.8 Elderly patients 
may also have cognitive impairment 
(even minor) and are often under-
diagnosed. They often have chronic 
conditions requiring long courses 
of treatment that can be confusing 
in combination with oral chemo-
therapy. In an ambulatory elderly 
population, Darnell et al found a 
compliance rate of 78% for a single 
long-term medication, 54% for 
three medications and only 21% for 
six concomitant medications.9 
Good adherence to capecitabine 
for patients with t(9;11) remained 
significantly longer even when only 
patients treated with HSCT in first 
remission were considered (Figure 
3), although numbers were small. 
All five patients with t(9;11) were 
treated with HSCT in CR1.
The data supports the conclu-
sion that MLL-positive t(9;11) 
AML patients should be classi-
fied differently from the rest of the 
MLL-rearranged cases and should 
be considered as part of the inter-
mediate-risk group. This classifica-
tion separating the t(9;11) cases 
from the rest of the MLL-positive 
cases should be maintained even 
when patients are treated with al-
logeneic HSCT. 
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